Trial Information - Phase II
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Disease Specifics: NSCLC KRAS G12C Mutation
Protocol ID: 849-001
Sponsor: Mirati Therapeutics, Inc
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
